Breast cancer metastasis suppressor gene 1 correlates with progression of cancer: a Metaanalysis

doi:10.3760/cma.j.issn.1673422X.2016.08.010

Abstract

Abstract: Objective To evaluate the association between the expression of breast cancer metastasis suppressor gene 1 (BRMS1) and the progression of cancer, and provide the basis for predicting the occurrence and metastasis of cancer. Methods Articles about BRMS1 with the clinical research literatures of cancer from PubMed, EMBase, China National Knowledge Infrastructure, Wanfang and VIP database were retrieved. The association between the expression of BRMS1 and tumorigenesis was evaluated by odds ratio (OR). The RevMan 5.3 software was used to complete the meta-analysis. Results A total of 27 articles were included, involving 2 282 cases in cancer group and 1 236 cases in the control group. The metaanalysis results showed that BRMS1 expression was significantly upregulated in cancer lesions compared with paired noncancer (OR= 0.10, 95%CI: 0.080.14, Z=15.37, P<0.000 01). In the subgroup about the type of cancers, there was statistically significant difference in the pooled OR between breast cancer and the control group (OR=0.10, 95%CI: 0.050.20, Z=6.18, P<0.000 01). Conclusion The level of BRMS1 is negatively correlated with tumorigenesis including breast cancer. Low or absent BRMS1 expression in the tumor tissue may be an adverse predictive factor of tumorigenesis and metastasis.

Key words: Neoplasms, Meta-analysis, Breast cancer metastasis suppressor 1

Pan Zhongya, Long Xinghua. Breast cancer metastasis suppressor gene 1 correlates with progression of cancer: a Metaanalysis[J]. Journal of International Oncology, 2016, 43(8): 603-608.

References

［1］ Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths［J］. CA Cancer J Clin, 2011, 61(4): 212-236. DOI: 10.3322/caac.20121. ［2］ Song S, Yuan Y, Lu J, et al. The drosophila ortholog of breast cancer metastasis suppressor gene, dBrms1, is critical for developmental timing through regulating ecdysone signaling［J］. Dev Biol, 2013, 380(2): 344-350. DOI: 10.1016/j.ydbio.2013.05.012. ［3］ Kodura MA, Souchelnytskyi S. Breast carcinoma metastasis suppressor gene 1 (BRMS1): update on its role as the suppressor of cancer metastases［J］. Cancer Metastasis Rev, 2015, 34(4): 611-618. DOI: 10.1007/s10555-015-9583-z. ［4］ Slipicevic A, Holm R, Emilsen E, et al. Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased diseasefree survival［J］. BMC Cancer, 2012, 12: 73. DOI: 10.1186/1471-2407-12-73. ［5］ Li J, Cheng Y, Tai D, et al. Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis［J］. Oncogene, 2011, 30(8): 896-906. DOI: 10.1038/onc.2010.470. ［6］ Kelly LM, Buggy Y, Hill A, et al. Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes［J］. Tumour Biol, 2005, 26(4): 213-216. DOI: 10.1159/000086955. ［7］ Mei P, Bai J, Shi M, et al. BRMS1 suppresses glioma progression by regulating invasion, migration and adhesion of glioma cells［J］. PLoS One, 2014, 9(5): e98544. DOI: 10.1371/journal.pone.0098544. ［8］ Yang Z, Liu F, Yang ZL. BRMS1 and HPA as progression, clinical biological behaviors, and poor prognosisrelated biomarkers for gallbladder adenocarcinoma［J］. Appl Immunohistochem Mol Morphol, 2016, 24(4): 275-282. DOI: 10.1097/PAI.0000000000000183. ［9］何雄斌, 吴海燕, 崔明. 转移相关基因BRMS1和MMP-9在乳腺癌中的表达及意义［J］. 实用癌症杂志, 2009, 24(4): 351-354. DOI: 10.3969/j.issn.1001-5930.2009.04.007. ［10］余德荣, 游力, 许晓群, 等. BRMS1 mRNA和CD44V6 mRNA在子宫内膜癌组织中的表达及意义［J］. 中华肿瘤防治杂志, 2007, 14(4): 287-290. DOI: 10.3969/j.issn.16735269.2007.04.013. ［11］刘国伟, 邱钢, 张萍. BRMS1在结肠癌组织中表达意义的研究［J］. 吉林医学, 2014, 35(13): 2788-2790. DOI: 10.3969/j.issn.1004-0412.2014.13.030. ［12］史本涛, 郑爱萍, 姜妮, 等. BRMS1基因在前列腺癌组织中的表达及临床意义［J］. 中国男科学杂志, 2013, 27(12): 3-6. DOI: 10.3969/j.issn.1008-0848.2013.12.001. ［13］吴作友, 陈斌. 乳腺癌组织中BRMS1和VEGF-C蛋白的表达及意义［J］. 实用医学杂志, 2011, 27(4): 572-574. DOI: 10.3969/j.issn.1006-5725.2011.04.009. ［14］吴宇, 刘辉. BRMS1和Cx43蛋白异常表达与甲状腺癌发生发展关系的研究［J］. 中国肿瘤临床, 2015, 42(11): 550-554. DOI: 10.3969/j.issn.1000-8179.20150322. ［15］吴海燕, 何雄斌, 胡玉林, 等. 结肠癌组织中BRMS1的表达及临床意义［J］. 山东医药, 2012, 52(31): 43-44. DOI: 10.3969/j.issn.1002-266X.2012.31.016. ［16］夏根玉, 陈斌. BRMS1、HDAC1、VEGF-C在乳腺癌组织中的表达及意义［J］. 中国现代医生, 2010, 48(9): 1012. DOI: 10.3969/j.issn.1673-9701.2010.09.005. ［17］崔明, 何雄斌, 吴海燕. BRMS1蛋白在乳腺癌中的表达及临床意义［J］. 临床外科杂志, 2009, 17(11): 756-758. DOI: 10.3969/j.issn.1005-6483.2009.11.017. ［18］年峰. BRMS1基因在食管鳞癌组织中的表达及意义［J］. 淮海医药, 2012, 30(3): 234-235. DOI: 10.3969/j.issn.1008-7044.2012.03.022. ［19］张云良. BRMS1、uPA在胃癌组织中表达及相关性研究［J］. 中国民康医学, 2013, 25(7): 38-40. DOI: 10.3969/j.issn.1672-0369.2013.07.013. ［20］张英, 陈丽娟, 刘永源. 乳腺浸润性导管癌中SATB1和BRMS1的表达及与淋巴转移的相关性［J］. 广东医学, 2015, 36(4): 532-537. ［21］曾晓波, 杨竹林. 慢性肝病和肝癌患者肝组织中乳腺癌转移抑制基因1和乙酰肝素酶的表达及其意义［J］. 中华肝脏病杂志, 2011, 19(11): 870-872. DOI: 10.3760/cma.j.issn.1007-3418.2011.11.020. ［22］毛莉, 杨永秀. 乳腺癌转移抑制基因1和核因子相关κB结合蛋白50在宫颈癌变中的表达［J］. 国际妇产科学杂志, 2014, 41(4): 370-373. ［23］王云, 赵治明, 陈蕾, 等. 鼻腔鼻窦恶性肿瘤中BRMS1基因蛋白表达的研究［J］. 临床耳鼻咽喉头颈外科杂志, 2011, 25(20): 920-921. DOI: 10.3969/j.issn.10011781.2011.20.003. ［24］王大勇. BRMS1和Survivin在乳腺癌中的表达及临床意义［J］. 河北医药, 2014, 36(3): 342-344. DOI: 10.3969/j.issn.1002-7386.2014.03.007. ［25］胡祖健, 徐海滨, 任兴昌, 等. 乳腺癌转移抑制基因、尿激酶型纤溶酶原激活剂在乳腺癌组织中的表达［J］. 全科医学临床与教育, 2015, 2(2): 132-134. DOI: 10.13558/j.cnki.issn1672-3686.2015.02.005. ［26］赵晓兰, 王平. SATB1、BRMS1在卵巢浆液性腺癌中的表达及其与临床病理特征的关系［J］. 四川大学学报(医学版), 2011, 42(1): 82-85, 105. ［27］郭星, 李晓瑜, 李福才, 等. 乳腺癌转移抵制基因和CD44v6在声门上型喉癌中的表达及临床意义［J］. 临床耳鼻咽喉头颈外科杂志, 2009, 23(6): 249-253. DOI: 10.3969/j.issn.1001-1781.2009.06.003. ［28］韩冬艳, 蒋虹伟, 朱延波. 乳腺癌转移抑制基因1在乳腺癌中的表达及其意义［J］. 上海医学, 2012, 35(6): 546-548. ［29］韩国新, 魏立伟, 王庆宝. BRMS1基因在胃癌中的表达及意义［J］. 山东医药, 2011, 51(41): 4647. DOI: 10.3969/j.issn.1002-266X.2011.41.025. ［30］饶玉梅, 陈刚, 李留霞, 等. BRMS1、整合素β1及p-AKT在卵巢癌组织中的表达及临床意义［J］. 中国当代医药, 2013, 20(23): 9-11. DOI: 10.3969/j.issn.16744721.2013.23.004. ［31］ Gong C, Qu S, Lv XB, et al. BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10［J］. Nat Commun, 2014, 5: 5406. DOI: 10.1038/ncomms6406. ［32］ Wang Q, Wei J, Su P, et al. Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression［J］. Biochem Biophys Res Commun, 2015, 464(2): 659-666. DOI: 10.1016/j.bbrc.2015.07.049. ［33］ Guo XL, Wang YJ, Cui PL, et al. Effect of BRMS1 expression on proliferation, migration and adhesion of mouse forestomach carcinoma［J］. Asian Pac J Trop Med, 2015, 8(9): 724-730. DOI: 10.1016/j.apjtm.2015.07.020. ［34］周映群, 生秀杰. 乳腺癌转移抑制基因1抑制肿瘤转移的机制［J］. 国际肿瘤学杂志, 2011, 38(6): 438-41. ［35］ Kong B, Lv ZD, Wang Y, et al. Down-regulation of BRMS1 by DNA hypermethylation and its association with metastatic progression in triplenegative breast cancer［J］. Int J Clin Exp Pathol, 2015, 8(9): 11076-11083. ［36］ Chimonidou M, Kallergi G, Georgoulias V, et al. Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells［J］. Mol Cancer Res, 2013, 11(10): 1248-1257. DOI: 10.1158/1541-7786.MCR-13-0096. ［37］ Yang J, Shen Y, Liu B, et al. Promoter methylation of BRMS1 correlates with smoking history and poor survival in nonsmall cell lung cancer patients［J］. Lung Cancer, 2011, 74(2): 305-309. DOI: 10.1016/j.lungcan.2011.03.002.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.